التفاصيل البيبلوغرافية
| العنوان: |
POS1045 Ixekizumab efficacy on spinal pain, disease activity and quality of life in patients with psoriatic arthritis presenting with symptoms suggestive of axial involvement |
| المؤلفون: |
Deodhar, A., Gladman, D. D., Bolce, R., Sandoval, D., Park, S. Y., Liu Leage, S., Nash, P., Poddubnyy, D. |
| المصدر: |
Annals of the Rheumatic Diseases ; volume 80, issue Suppl 1, page 798-799 ; ISSN 0003-4967 1468-2060 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
General Biochemistry, Genetics and Molecular Biology, Immunology, Immunology and Allergy, Rheumatology |
| الوصف: |
Background: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness, which may suggest axial involvement [1]. The prevalence of axial involvement in PsA varies between 25-70% [2]. Ixekizumab (IXE), a monoclonal antibody with high affinity for IL17-A, has been studied in Phase 3 trials in patients with PsA (SPIRIT-P1 [Biologic-naïve; NCT01695239 ] and SPIRIT-P2 [Inadequate response or intolerant to 1 or 2 TNF inhibitors (TNFi); NCT02349295 ]) [3] [4]. Objectives: To determine the efficacy of IXE up to 52 weeks (Wks) in reducing axial symptoms in patients with active PsA presenting with symptoms suggestive of axial involvement. Methods: This post-hoc analysis included data from two subpopulations of patients with PsA (pooled SPIRIT-P1 and -P2). Symptoms suggestive of axial involvement were defined as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q2 (back pain) ≥4, and an average of Q5 + Q6 (intensity and duration of morning stiffness in the spine) ≥4 at baseline. Patients included in the sensitivity analysis subgroup 1 were, in addition to the above-mentioned overall analysis criteria, <45 years of age, while patients included in sensitivity analysis subgroup 2 were aged <45 but also had elevated C-reactive protein (CRP) (> 5 mg/l) at baseline. Efficacy of IXE was analysed using BASDAI questions, total BASDAI, mBASDAI (without Q3), and Ankylosing Spondylitis Disease Activity Score (ASDAS) change from baseline, as well as BASDAI50 response and Short-Form-36 physical component summary (SF-36 PCS) improvement, at Wks 16, 24 and 52. Treatment comparison was done using logistic regression for BASDAI50, and analysis of covariance (ANCOVA) model for other endpoints. Missing data for binary and continuous endpoints were imputed by non-responder imputation and modified baseline observation carried forward (mBOCF), respectively. Results: A total of 313 patients (placebo (PBO), N=151; IXE Q4W, N=162) met the overall analysis inclusion criteria. Baseline values for BASDAI and ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/annrheumdis-2021-eular.1570 |
| الإتاحة: |
https://doi.org/10.1136/annrheumdis-2021-eular.1570Test |
| رقم الانضمام: |
edsbas.45DEEB7A |
| قاعدة البيانات: |
BASE |
